Picture of Xvivo Perfusion AB logo

XVIVO — Xvivo Perfusion AB News Story

0.000.00%
se flag iconLast trade - 00:00
HealthcareSpeculativeMid CapFalling Star

Brief: Xvivo Q2 EBITDA Decreases TO SEK 5.3 Million

Oct 21 (Reuters) - Xvivo Perfusion AB  XVIVO.ST :
    * XVIVO PRESENTS INTERIM REPORT JANUARI-SEPTEMBER 2021
    * Q3 NET SALES AMOUNTED TO SEK 54.9 MILLION (42.7),
CORRESPONDING
TO AN INCREASE OF 29 PERCENT IN SEK AND 31 PERCENT IN LOCAL
CURRENCIES.
    * Q3 NET SALES OF NON-DURABLE GOODS AMOUNTED TO SEK 48.9
MILLION
(42.3),
    * Q3 ADJUSTED OPERATING PROFIT BEFORE DEPRECIATION AND
AMORTIZATION (EBITDA) AMOUNTED TO SEK 5.3 MILLION (9.3)
    * Q3 REPORTED EBITDA AMOUNTED TO SEK 4.2 MILLION (-11.2)

Source text for Eikon:  ID:nMFN5vWfvf 
Further company coverage:  XVIVO.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))

Recent news on Xvivo Perfusion AB

See all news